netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Recent Updates - Updated items

All Formulary Amendments

  Records 1 to 15 of 15


Details
UPD sitematrix Changed from 0 to
10/10/2023 13:16:01
(DavidS )
UPD FurtherInformation Changed from
  • Approved for the treatment of severe refractory eosinophilic asthma in line with NICE and NHS England Commissioning Policy.
to
10/10/2023 13:16:01
(DavidS )
UPD Mepolizumab (Nucala®) addition of formulation details
10/10/2023 13:16:01
(DavidS )
UPD sitematrix Changed from 0 to
10/10/2023 13:14:50
(DavidS )
UPD FurtherInformation Changed from

  • Approved for the treatment of severe refractory eosinophilic asthma in line with NICE and NHS England Commissioning Policy.

to
10/10/2023 13:14:50
(DavidS )
UPD Mepolizumab (Nucala®) amended formatting
10/10/2023 13:14:50
(DavidS )
UPD Mepolizumab (Nucala®) updated
25/04/2019 14:52:42
(DavidS )
UPD Mepolizumab (Nucala®) approved
11/08/2017 14:52:21
(LoweryM )
UPD Mepolizumab (Nucala®) updated
09/08/2017 16:59:13
(DavidS )
UPD Mepolizumab Published from Draft Mode
26/04/2017 10:25:58
(LoweryM )
UPD Mepolizumab (Nucala®) updated
25/04/2017 13:22:09
(LoweryM )
LDL Link Added : NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma : https://www.nice.org.uk/guidance/ta431
24/04/2017 14:17:01
(DavidS )
UPD Mepolizumab (Nucala®) a
24/04/2017 14:16:38
(DavidS )
UPD Mepolizumab (Nucala®) formatting change
24/04/2017 14:16:28
(DavidS )
ADD Mepolizumab (Nucala®) Approved by NICE (TA431)
24/04/2017 14:15:12
(DavidS )

 

 
netFormulary